ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 11

Possible Therapeutics for Antiphospholipid Antibody Related Thrombocytopenia: A Systemic Review and Meta-Analysis

Nobuya Abe1, Kenji Oku1, Olga Amengual1, Yuichiro Fujieda1, Masaru Kato1, Toshiyuki Bohgaki1, Shinsuke Yasuda1, Rintaro Mori2, Eriko Morishita3, Katsue Suzuki-Inoue4 and Tatsuya Atsumi1, 1Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, 2Department of Health Policy, National Center for Child Health and Development, Tokyo, Japan, 3Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan, 4Department of Clinical and Laboratory Medicine, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Antiphospholipid antibodies, meta-analysis and thrombocytopenia

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 5, 2017

Session Title: Antiphospholipid Syndrome Poster

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Despite the pro-thrombotic nature of antiphospholipid antibodies (aPL), thrombocytopenia is frequently observed in patients with antiphospholipid syndrome (APS) or in non-APS patients with aPL. The management of the thrombocytopenia with aPL (aPL related thrombocytopenia; APAT) is often deductive, due to the paradoxical risks of thrombosis and hemorrhage. We have been striving to clarify the mechanisms of APAT and reported its high prevalence of arterial thrombotic events (Nakagawa I, et al. ACR 2014, Abstract #2). In the present study, along with the reconfirmation of the clinical importance of APAT, we aimed to evaluate the efficacy of therapeutic regimes in APAT through a systematic review of the literature with the objective of elaborating a clinical practice guideline for APAT on a consignment project from the Japanese Ministry of Health, Labor and Welfare.

Methods: Four clinical questions were selected for systematic review and redefined using the PICO (Patient, Intervention, Comparison, Outcome) format and prioritized. The four clinical questions were to evaluate the effects of possible therapeutics for APAT; antiplatelet agents, glucocorticoids, splenectomy and thrombopoietin receptor agonists. Systematic reviews were performed using electronic databases (MEDLINE, EMBASE and CENTRAL) by the Cochrane Japan Centre. Cochrane Collaboration Review Manager software was used to manage and analyze the data collected.

Results: The initial search yielded 1407 citations of which nine were included in our final analysis. There was no randomized controlled trial on treatment for APAT. We identified four case-controlled studies for splenectomy, one for antiplatelet agents and four observational studies for glucocorticoids. Meta-analysis of quantitative data (17/23) showed evidence of an increase in platelet count in patients who underwent splenectomy compared with the patients without splenectomy (mean difference 22.6~104 /mL, P = 0.007) (Figure). Complete remissions of the thrombocytopenia were observed in 18/23 (78%) patients with splenectomy versus 0/23 (0%) without splenectomy. The relapses were occurred in 3/23 (13%) patients with splenectomy. There was no complications due to splenectomy. None of the configured outcomes were susceptible to the antiplatelet and glucocorticoid therapy.

Conclusion: Although splenectomy for APS was previously reported to be a risk of portal vein thrombosis, our systematic review and meta-analysis revealed that it may be performed rather safely and effectively in APAT patients. However, there was no clear evidence to support applications of antiplatelet agents, glucocorticoids, or thrombopoietin receptor agonists as therapeutics of APAT. Further clinical trials are required to establish therapeutic recommendation for APAT.


Disclosure: N. Abe, None; K. Oku, None; O. Amengual, None; Y. Fujieda, None; M. Kato, None; T. Bohgaki, None; S. Yasuda, None; R. Mori, None; E. Morishita, None; K. Suzuki-Inoue, None; T. Atsumi, None.

To cite this abstract in AMA style:

Abe N, Oku K, Amengual O, Fujieda Y, Kato M, Bohgaki T, Yasuda S, Mori R, Morishita E, Suzuki-Inoue K, Atsumi T. Possible Therapeutics for Antiphospholipid Antibody Related Thrombocytopenia: A Systemic Review and Meta-Analysis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/possible-therapeutics-for-antiphospholipid-antibody-related-thrombocytopenia-a-systemic-review-and-meta-analysis/. Accessed May 19, 2022.
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/possible-therapeutics-for-antiphospholipid-antibody-related-thrombocytopenia-a-systemic-review-and-meta-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.